TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Emotions Analysis in Patients With Chronic Phase of Stroke Basal Ganglia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For cases :~  * right-handed patient~ * ischemic or hemorrhagic stroke older than 3 months with single lesion preferably less than 20 mm in diameter affecting the basal ganglia and sparing cortex~ * Rankin score estimated prior stroke must be equal to 0 and after stroke \<3 (at inclusion).~* For participants control : right-handed patient~Exclusion Criteria:~* For cases : severe aphasia - Prosopagnosia apperceptive - cerebral neurological pathology associated history, especially dementia - History of depression and psychiatric disorders treated - another stroke vascular territory than that for which the patient is included - diffuse lesions of the white matter Fazekas a score of\> 2 (periventricular or subcortical) - Contraindications to MRI~* For participants control : No history neurosurgical - No history of head trauma with loss of consciousness - not known neurological disease - not known psychiatric illness - No psychotropic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Emotional induction in stroke population (Type: OTHER): Six films are presented, each after a relaxation period after which the basal score is measured.
- Emotional induction in healthy volunteers (Type: PLACEBO_COMPARATOR): Six films are presented, each after a relaxation period after which the basal score is measured.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histological documented uveal melanoma~* HLA-A2.1 phenotype (intervention arm)~* non-HLA-A2.1 phenotype (control arm)~* melanoma expressing gp100 and/or tyrosinase~* high risk genetic profile (loss of chromosome 3) determined by FISH~* interval since local treatment of uveal melanoma \< 12 months~* no signs of liver metastasis determined by diagnostic CT-abdomen~* normal serum LDH~* no signs of cerebral metastases~* bilirubin \< 25 micromol/l~* WHO performance scale 0-1~* age 18-75 years~* written informed consent~* expected adequacy of followup~* no pregnant or lactating women~Exclusion Criteria:~* history of second malignancy, except adequately treated basal cell carcinoma~* serious active infections~* autoimmune disease or organ allografts~* concomitant use of immunosuppressive drugs~* known allergy to shell-fish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- dendritic cell vaccination (Type: EXPERIMENTAL): HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
- control arm (Type: NO_INTERVENTION): For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. A confirmed diagnosis of IMO with documented TCIRG1 mutation.~2. Age at least 1 month with minimum weight of 4 kg~3. Absence of debilitating hydrocephalus (defined as hydrocephalus at NCI CTCAE v5.0 Grade 3 or higher persisting despite shunt or similar procedural intervention).~4. Lansky Play Scale of at least 60%~5. Preserved hepatic function (AST/ALT ≤3.0 ULN; bilirubin ≤1.5 ULN; to minimize potential for excessive toxicity from busulfan conditioning)~6. No concomitant medical or other conditions that would represent a contraindication to autologous hematopoietic stem cell transplant.~7. Absolute neutrophil count of ≥500/mm3 and platelet count of ≥25,000/mm3~8. No prior allogeneic or other hematopoietic stem cell transplant.~9. Availability of a non-autologous rescue (back-up) hematopoietic stem cell donor/source~Exclusion Criteria:~1. Availability of medically-feasible HLA-matched sibling donor for allogeneic HSCT.~2. Any medical or other contraindication for either apheresis or autologous transplant as determined by the Investigator.~3. Participation in another clinical trial with an investigational drug within 14 days before the informed consent signature. Participation in observational studies is allowed.~4. Active hematologic or solid organ malignancy, not including non-melanoma skin cancer or another carcinoma in situ.~5. Uncontrolled seizure disorder.~6. Renal dysfunction as defined by a glomerular filtration rate \<30 mL/min/1.73m2 or dialysis dependence.~7. Serious infections with persistent bloodstream pathogens at time of trial entry~8. Pulmonary dysfunction as defined by either:~   * Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection) or~  * Oxygen saturation (by pulse oximetry) \<90% resulting from pulmonary conditions (intermittent hypoxia secondary to IMO-related choanal atresia will not be considered exclusionary)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental - RP-L401 (Type: EXPERIMENTAL): RP-L401 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with lentiviral vector carrying the TCIRG1 transgene

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Viscous Lidocaine for Upper Gastrointestinal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred to and found fit for upper GI endoscopy in an out patient setting~* Between 18 and 75 years old~* Speaks and understands Danish~Exclusion Criteria:~* Patients admitted for upper GI endoscopy in an in-patient setting~* Patients with dementia and/or other cognitive dysfunction disorders~* Patients primarily complaining of dysphagia~* Patients allergic to lidocaine~* Patients with suspected retention~* Patients who will undergo upper GI endoscopy with nurse-assisted propofol sedation~* Patients who will undergo upper GI endoscopy with assistance of anesthesia-personnel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Viscous lidocaine (Type: EXPERIMENTAL): Oral viscous lidocaine 20 mg/ml, 10 ml
- Placebo (Type: PLACEBO_COMPARATOR): Oral viscous solution without active drug, 10 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Fistula Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To participate in this study, the subject MUST have all of the following for inclusion in the study:~* The subject must be \> 18 years of age, male or female~* Subject requires creation of dialysis access secondary to ESRD in the opinion of the referring nephrologist~* Target arm may have a failed radiocephalic fistula~* Contralateral failed or failing access may exist~* The subject must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board.~Exclusion Criteria:~To participate in this study, the subject may NOT HAVE any of the following at enrollment to the study:~* Target arm has existing forearm AV graft, either functional or non-functional~* Target arm has existing fistula, either functional or non-functional, other than a radio-cephalic at the wrist~* Target arm has documented subclavian vein occlusion~* Target arm has obviously suitable cephalic vein and radial artery for a primary radiocephalic fistula~* Target arm has no superficial veins existing as options for primary access. If so, a second surgeon will review the ultrasound to confirm~* Active local or systemic infection at the time of surgery~* Known hypercoagulable state (e.g., antithrombin III deficiency, antiphospholipid or anticardiolipin antibodies, Factor IV Leiden, circulating lupus anticoagulant, history of heparin-induced thrombocytopenia, Protein C or S deficiency, prothrombin mutation or a history of recurrent deep venous thrombosis and/or pulmonary embolism)~* Disseminated malignancy or other terminal condition where subject is expected to live less than 6 months.~* Previous randomization in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Alternative Fistula (Type: ACTIVE_COMPARATOR): None
- 2 Forearm AV Graft (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Responsiveness to Treatment by Experience Sampling Method

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 75 years;~* A diagnosis of IBS-C according to Rome IV criteria:~Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with 2 or more of the following criteria: 1) Relation to defecation; 2) Association with a change in stool frequency; 3) Association with a change in stool form (appearance). Criteria fulfilled for the last 3 months with symptom onset at least 6 months ago. Reported stool consistency over the last 3 months: At least 25% of bowel movements are hard and lumpy stools (BSFS 1 or 2) and less than 25% of bowel movements are watery stools (BSFS 6 or 7).~* Negative colonoscopy in the past 5 years prior to inclusion;~* Treatment in primary care unsuccessful for 12 months;~* Ability to understand, read and speak the Dutch language;~* Ability to understand how to utilize the MEASuRE app on a smartphone.~Exclusion Criteria:~* Appendectomy or cholecystectomy within 2 months or other abdominal surgeries within 6 months before entry into the study;~* A history of laxative abuse;~* Current use of drugs that could initiate constipation (e.g. narcotics);~* Use of any IBS-related drugs possibly causing constipation (e.g. tricyclic antidepressants) are a reason for exclusion, unless usage is on a stable dose for at least 30 days before inclusion and there is no plan to change the dose during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBS-C (Type: None): Constipation-predominant irritable bowel syndrome

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for subproject MCS-2~* Age ≧ 40 years old.~* Not being treated for BPH or LUTS with Alpha-blocker, anti-cholinergics, 5-alpha reductase inhibitors, or hormonal agents.~* PSA≦4 ng/ml within 4 weeks of V1 and no pathologically-proven prostate cancer.~* No known malignancy, except cancers without signs of recurrence for \> 5 years and no need for further anti-cancer treatment.~* AST/ALT≦3X UNL.~* creatinine≦3X UNL.~* Subjects who sign the informed consent form.~Exclusion criteria~* Subjects' LUTS are not BPH-related but are associated with such conditions as urethral stricture, prostatitis, neurogenic bladder, or pelvic treatment procedures.~* Have been treated with pelvis irradiation or pelvic surgery.~* Plan to undergo any invasive procedures within the study period, such as, prostate surgery, prostate biopsy, cystourethroscopy, pelvic surgery, laparotomy, or any procedures needing urethral catheterization.~* Participating in another investigational agent study in the past 12 weeks or are going to do so during the study period.~* Active infection or inflammation.~* Considered ineligible by the investigators.~Inclusion criteria for subproject MCS-3~* Age≧40 years old.~* The alpha-blocker dosage used should be as high as subjects can tolerate.~* No known malignancy, except cancers without signs of recurrence for \> 5 years and no need for further anti-cancer treatment.~* PSA≦10.0 ng/ml without pathologically-proven prostate cancer or other cancers. Prostate biopsy is mandatory \> 12 weeks before screening, if PSA is≧4 ng/ml to rule out prostate cancer.~* AST/ALT≦3X UNL.~* Creatinine≦3X UNL.~* Subjects who sign the informed consent form.~Exclusion criteria~* Subjects' LUTS are not BPH-related but associated with such conditions as urethral stricture, prostatitis, neurogenic bladder, or pelvic treatment procedures.~* Subjects who have been treated with pelvis irradiation or pelvic surgery.~* PSA \> 10.0 ng/ml, abnormal DRE of the prostate or any suspicion of prostate malignancy. However, those who have a negative prostate biopsy are allowed.~* Active infection or inflammation.~* Considered ineligible by the investigators.

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MCS (Type: ACTIVE_COMPARATOR): Group A: MCS 30 mg/day for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 2 capsules per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pemetrexed for Second-Line Pancreas Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the pancreas~* Prior treatment for distant or locally advanced disease with gemcitabine-based therapy~* Measurable or evaluable disease~* ECOG performance status 0-2~* Adequate hematological parameters~* Adequate baseline liver function~* At least 28 days from any major surgery~* At least 2 weeks from the last radiation treatment~* Must have recovered from reversible toxicities of prior chemotherapy~* Must be able to discontinue any nonsteroidal anti-inflammatory medications~* Must be willing to receive intramuscular vitamin B12 shots and take oral folate supplements~Exclusion Criteria:~* Any prior treatment with pemetrexed~* More than one prior chemotherapy regimen~* HIV positive on antiretroviral therapy~* Pregnant or lactating~* Prior organ allograft~* On concurrent antitumor therapy including radiation therapy or other chemotherapies~* Creatinine clearance 45 ml/min or less~* Absolute neutrophil count \< 1500~* Platelets \< 75,000~* Bilirubin \> 1.5 times the upper limit of normal~* Transaminases \> 3 times the upper limit of normal except in known liver metastasis wherein they may be \</= 5 times upper limit of normal~* Clinically significant ascites or pleural effusion that cannot be drained~* Any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: EXPERIMENTAL): pemetrexed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Validation of ICG to Identify the Urethra During Rectal Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study.~* Male, aged 18 years or above.~* Undergoing low rectal surgery where the operating field will be close to the urethra~Exclusion Criteria:~* Participant has an allergy to iodine or ICG~* Known liver failure

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Urethral instillation of ICG (Type: EXPERIMENTAL): Urethral instillation of indocyanine green (ICG)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Self-Help Video for Insomnia in College Students

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a student at The University of Alabama~* Must be 18-24 years old~* Must have a complaint of insomnia~Exclusion Criteria:~* history of sleep disorder other than insomnia~* symptoms strongly suggestive of sleep disorders other than insomnia~* shift-work~* history of severe mental illness (e.g., psychotic disorders, bipolar disorder, severe depression, or personality disorders)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Abbreviated cognitive behavioral therapy (Type: ACTIVE_COMPARATOR): Arm 1 is a multi-component package including sleep hygiene, stimulus control, cognitive therapy, and passive relaxation.
- Sleep education/sleep hygiene (Type: ACTIVE_COMPARATOR): Arm 2 consists of education about sleep and fatigue as well as sleep hygiene recommendations (e.g., avoiding nicotine and caffeine late in the day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Radial Reload Laparoscopic LAR Case Series

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject is able to understand and sign Informed Consent Form.~2. The subject is between 18-85 years of age.~3. The subject is anticipated to undergo a resection of the rectum with anastomosis below the peritoneal reflection.~4. The subject is anticipated to undergo mobilization and stapling of the rectum laparoscopically.~Exclusion Criteria:~1. Any female patient, who is pregnant, suspected pregnant, or nursing.~2. The participant is unable or unwilling to comply with the study requirements, follow-up schedule.~3. The participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Covidien Radial Reload Stapler with Tri-Staple Technology (Type: EXPERIMENTAL): Covidien Radial Reload Stapler with Tri-Staple Technology in laparoscopic LAR or proctosigmoidectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine in Patients With Tourette's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* High impulsive patients, aged 10-35 years old, diagnosed for Tourette's syndrome as defined by the DSM-IV, never treated by Atomoxetine~* The use of effective contraception or abstinence for subjects of reproductive age~* Written informed consent~Exclusion Criteria:~* Patients with mental retardation, psychotic disorders as schizophrenia, autism spectrum disorders, chronic tics which do not respond to Tourette's syndrome criteria.~* Actual severe depression~* Allergy to one of the constituents~* Severe cardiovascular or cerebrovascular diseases, Pheochromocytoma, uncontrolled hyperthyroidism, closed angle glaucoma~* IMAO treatment discontinued less than 2 months or contra-indicated associated treatment

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- patients with Tourette's syndrome (Type: EXPERIMENTAL): Atomoxetine in Patients With Tourette's Syndrome

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Proton Radiation Therapy for Pituitary Adenoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven pituitary adenoma.~* Age 18 years or older.~* Status post biopsy, gross total resection (from initial surgery for recurrent disease) or subtotal resection.~* Good to moderate neurological function status~Exclusion Criteria:~\*Previous radiation that would compromise the ability to deliver the prescribed treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Proton Radiation (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues